Physician profile
Xin Tan
NPI 1235117979
$6,484.50
in general payments reported to CMS, 2019-2025
34 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $435 · 2021: $916 · 2022: $778 · 2023: $1,302 · 2024: $1,546 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,058.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $1,247.37 | 2022-2025 | Ibsrela |
| Abbvie INC. | $912.18 | 2019-2025 | Linzess, Creon, Viberzi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $692.15 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $685.48 | 2019-2023 | |
| Novo Nordisk INC | $608.45 | 2021-2025 | Rybelsus, Ozempic, Norditropin |
| Nestle Healthcare Nutrition INC. | $378.38 | 2021-2023 | |
| Gilead Sciences, INC. | $278.14 | 2024-2025 | |
| Amgen INC. | $238.06 | 2021-2025 | Repatha, Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $194.80 | 2024-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $167.16 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $146.54 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $140.86 | 2023-2024 | Linzess |
| Allergan, INC. | $108.00 | 2019-2020 | |
| Astellas Pharma US INC | $88.24 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $69.87 | 2024-2025 | Gemtesa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.89 | 2020-2022 | |
| Pfizer INC. | $53.84 | 2021-2023 | |
| Cranial Technologies, INC | $46.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $39.85 | 2023-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $38.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $35.51 | 2021 | |
| Ibsa Pharma INC. | $29.83 | 2021 | |
| Mallinckrodt Hospital Products INC. | $28.63 | 2020 | |
| Fresenius USA Marketing, INC. | $20.74 | 2025 | Velphoro |
| Scilex Pharmaceuticals INC. | $20.64 | 2020 | |
| Paratek Pharmaceuticals, INC. | $20.32 | 2023 | Nuzyra |
| Esperion Therapeutics, INC. | $19.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.88 | 2022 | |
| Redhill Biopharma INC. | $18.79 | 2021 | |
| Sobi, INC | $16.82 | 2022 | |
| Genentech USA, INC. | $16.74 | 2019 | |
| Travere Therapeutics, INC. | $16.53 | 2023 | |
| Aimmune Therapeutics, INC. | $15.42 | 2024 | |
| Horizon Therapeutics Plc | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xin Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.